Citeline starts at ~$15,000/year. DataLookout starts at $0.
That's roughly 25x cheaper for the clinical trial monitoring use case — with daily email digests, no login required, and no procurement process.
What Citeline and Evaluate Pharma are great at
Before making the case for DataLookout, it's worth being honest about what the enterprise platforms do well. Citeline (formerly Informa Pharma Intelligence) and Evaluate Pharma are comprehensive intelligence platforms — they cover:
- Financial data, deal tracking, and company valuations
- Analyst forecasts, consensus revenue projections, and peak sales models
- Patent databases and regulatory filing timelines
- ClinicalTrials.gov data enriched with analyst commentary
- Pre-built therapeutic area landscape reports
- Large pharma-grade search and filtering across decades of data
If you're a corporate strategy team at a top-20 pharma company that needs all of these capabilities in one platform, Citeline and Evaluate Pharma are worth the price.
Where the enterprise platforms create a gap
The problem with Citeline and Evaluate Pharma is the same as most enterprise software: they're designed for the biggest buyers, with pricing and procurement processes to match. This creates a real gap for:
- Small and mid-size biotechs ($50M–$2B) that can't justify $15,000+/year for a seat
- Individual BD professionals who need monitoring but can't get budget approval
- Academic medical centers tracking clinical programs in their disease areas
- Investors who want trial status monitoring without a full enterprise intelligence subscription
- Teams that need only the ClinicalTrials.gov monitoring layer — not financial data, not analyst forecasts
DataLookout is built for this gap. We don't try to replicate everything Citeline does. We do one thing well: monitor ClinicalTrials.gov daily and tell you what's new in the areas you care about.
Head-to-head comparison
| Feature | Citeline | Evaluate Pharma | DataLookout |
|---|---|---|---|
| ClinicalTrials.gov monitoring | Yes | Yes | Yes — daily scan |
| Daily email alerts | Custom setup | Custom setup | Built-in, default |
| Financial forecasts | Yes | Yes (core feature) | No |
| Deal/M&A database | Yes | Yes | No |
| Patent database | Yes | Limited | No |
| Data source | Multi-source + enriched | Multi-source + enriched | ClinicalTrials.gov |
| Setup time | Weeks (procurement) | Weeks (procurement) | 2 minutes |
| Contract required | Annual, multi-seat | Annual | No — month-to-month |
| Starting price | ~$15,000–$50,000/yr | ~$10,000–$30,000/yr | Free → $49/month |
Is DataLookout the right fit for you?
Good fit — DataLookout works well if:
You primarily need to monitor ClinicalTrials.gov for competitive intelligence and don't need financial forecasts or deal databases. You're a small/mid biotech, individual BD professional, or investor who can't justify enterprise pricing. You want daily alerts that arrive in your inbox without logging into another platform.
Not the right fit if:
You need revenue forecasts, analyst consensus models, or patent data alongside trial monitoring. Your workflow requires a full enterprise intelligence platform with built-in collaboration, compliance features, or large team access. You're at a top-20 pharma and budget is not a constraint.
Try DataLookout — free, no card required
Set up a monitoring profile in 2 minutes. Daily digests start tomorrow. Cancel or change any time.
How DataLookout handles the monitoring layer
Daily scan of ClinicalTrials.gov
Every morning, DataLookout queries the ClinicalTrials.gov API for new and updated studies. We check for: new registrations, status changes (recruiting, active, completed, terminated), enrollment count changes, and protocol amendments. Anything matching your keyword profiles goes into your digest.
Keyword-based profile filtering
You define what you want to monitor — disease areas, drug targets, company names, or any combination. A profile like "NASH MASH metabolic dysfunction-associated steatohepatitis" will capture every liver disease trial in that space, regardless of which specific terminology the sponsor uses.
Email digest, no dashboard required
The digest arrives by email each morning. Each trial links directly to its ClinicalTrials.gov record. No separate login, no dashboard to check, no alerts that pile up in an app you forget to open. It integrates with however you already work.
Frequently asked questions
Does DataLookout cover the same trials as Citeline?
DataLookout's source is ClinicalTrials.gov, which is the same underlying registry that Citeline and Evaluate Pharma include. Citeline enriches this data with analyst commentary, financial context, and other proprietary data sources. DataLookout delivers the registry data itself — clean, daily, and filterable — without the enrichment layer.
Can I use DataLookout alongside Citeline?
Yes. Some users maintain a Citeline subscription for quarterly landscape work and use DataLookout for daily monitoring. The daily email format makes it easy to stay on top of changes without logging into a separate platform. At $49/month, DataLookout adds daily alerting coverage to teams that already have (or are between) enterprise subscriptions.
How current is the data?
DataLookout scans ClinicalTrials.gov daily. New registrations and updates typically appear in your digest within 24 hours of posting to the registry. ClinicalTrials.gov itself requires sponsors to update records within 30 days of any protocol change, so the registry is the authoritative source.
What if I cancel?
Cancel any time — no annual contract, no cancellation fee. Your digests stop at the end of the billing period. Email [email protected] to cancel or change your plan.